The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009
Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006
The inhibition of MRP4, a new target in pulmonary hypertension (PH), prevents and reverses hypoxia-induced pH in mice Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009
Effects of apoptosis signal- regulating kinase 1 (ASK1) inhibition in experimental pressure overload-induced right ventricular dysfunction Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Shroom expression is attenuated in hypoxia-induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 147s Year: 2006
Aminoguanidine attenuates bleomycin-induced pulmonary fibrosis in rats through inhibition of heat shock protein 47 and TGF-β1 expression Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
TSC1/mTOR pathway promotes hypoxia-induced pulmonary hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Eur Respir Rev 2008; 17: 72-73 Year: 2008
Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007
Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodelling in an asthma model in mice Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017
Simultaneous inhibition of CTGF and Autotaxin reduces lung fibrosis and improves lung function in mice Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008
Adrenergic receptor blocker reverses cardiac metabolic remodeling and improves right ventricular function in experimental pulmonary hypertension Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011
Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017